Two patients with high-level FGFR2-amplified metastatic gastric cancer were successfully treated with futibatinib after progression on multiple lines of chemotherapy, with significant tumor shrinkage, symptom relief, and reduced tumor marker levels. Here, FGFR2 is linked to neoplasm.